THERAPY DOSSIER · th-032936a9e3cf

Nebivolol

Drug · Beta-adrenergic receptor antagonist (beta-1 selective; nitric-oxide-mediated vasodilation)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Beta-adrenergic receptor antagonist (beta-1 selective; nitric-oxide-mediated vasodilation)
Target: Beta-1 adrenergic receptor (CHEMBL213); Beta-2 adrenergic receptor (CHEMBL210)
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: 2007
Development stage: Not recorded
ChEMBL record: CHEMBL434394 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Nebivolol; Bystolic; Nebilet; Hypoloc
Note: Not recorded

Clinical trials 4

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00517725 ↗PHASE4completed

Trial title not recorded

Chronic Heart Failure

Enrolment: 60 · Results not recorded

NCT01230892 ↗PHASE4completed

Trial title not recorded

Atherosclerosis

Enrolment: 29 · Results not recorded

NCT00683124 ↗PHASE3unknown

Trial title not recorded

Marfan Syndrome

Enrolment: 291 · Results not recorded

NCT00547300 ↗PHASE3terminated

Trial title not recorded

Hypertension

Enrolment: 49 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28118507 ↗2017Reported benefit

Pretreatment with nebivolol attenuates level and expression of matrix metalloproteinases in a rat model of renal ischaemia-reperfusion injury.

RatIschaemia-reperfusionRenalWistar albinoMalen = Twenty Wistar albino rats divided into three groupsPretreatment before ischaemia-reperfusion, exact interval not stated in the abs…

Model: Bilateral clamping of the renal arteries for 45 min followed by 24 h of reperfusion

Nebivolol pretreatment significantly reduced the quantity and expression of MMP-2 and MMP-9 during renal ischaemia-reperfusion injury and lowered tubular injury scores compared with untreated injured rats.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…